GLIMPSES ON COVID-19 AND 2-DEOXY D-GLUCOSE AS A NOVEL APPROACH IN EMERGENCY TREATMENT: A REVIEW
Jerin James* and Soji S.
Abstract
Covid 19 is a highly infectious disease caused by severe acute
respiratory syndrome coronavirus 2. It destructively spread all over the
world. COVID-19 was identified in Wuhan City of China, on
December 12th, 2019. Dr. Tedros Adhanom Ghebreyesus declared that
the infection developed due to severe acute respiratory syndrome
coronavirus 2 is “COVID-19” on February 11th, 2020. From the
beginning, most treatment strategies were focused on symptomatic
management and supportive therapy only. But now vaccines are also
available. Recently, for emergency purposes, India's drug controller
general has authorized “2-Deoxy-D-glucose” as an adjunct treatment.
This review aims to provide some information about recently
introduced 2-deoxy D-glucose. The lack of hydroxyl group at the
second position makes this drug differ from glucose. It inhibits the living cell's glycolysis
pathway and contains viral replication. As per the phase II clinical trial, it showed a positive
outcome and reduced oxygen dependence. Now phase III is going on several hospitals across
India. But studies showed some adverse effects also.
Keywords: Covid-19, 2-Deoxy-D-glucose, Glycolysis, Clinical trial, Adverse effect.
[Full Text Article]